株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

治療法における提携の動向

Trends in Therapeutic Partnering 2010-2015

発行 Current Partnering, a division of Wildwood Ventures Limited 商品コード 278099
出版日 ページ情報 英文
納期: 即日から翌営業日
価格
こちらの商品の販売は終了いたしました。
Back to Top
治療法における提携の動向 Trends in Therapeutic Partnering 2010-2015
出版日: 2015年07月06日 ページ情報: 英文

当商品の販売は、2016年06月03日を持ちまして終了しました。

概要

当レポートでは、治療法における提携動向について詳細に調査分析し、提携機会の提示方法、主な提携イベントの紹介、および提携の主要な治療標的35領域の分析などを提供しており、概略下記の構成でお届けいたします。

エグゼクティブサマリー

第1章 イントロダクション

第2章 治療契約活動における動向

  • イントロダクション
  • 主な治療提携領域
  • 提携の主な治療標的

第3章 主な治療契約:金額別

  • イントロダクション
  • 大手製薬企業の治療提携
  • 大手バイオテクノロジー企業の治療提携

第4章 治療標的の提携企業への機会の提示

  • どのように機会を提示するか
  • 機会を提示するテンプレート
  • eメールの送付
  • 提携イベントでの直接対面
  • オンラインによる提示の形式

第5章 間近に迫った治療提携イベント

  • 間近のイベント

第6章 提携における治療標的の主要35分野

  • イントロダクション
  • 治療法プロファイル
  • 糖尿病
  • 中枢神経系疼痛
  • 乳がん
  • アルツハイマー病
  • 肺がん
  • 創傷治癒
  • HIV
  • 炎症
  • インフルエンザ
  • 前立腺がん
  • 白血病
  • 栄養・ビタミン
  • 固形腫瘍
  • パーキンソン病
  • 結腸直腸がん
  • 関節リウマチ
  • 多発性硬化症
  • 整形外科
  • 事故・救急
  • C型肝炎
  • 移植
  • 肥満
  • 卵巣癌
  • リンパ腫
  • 結核
  • 脊髄
  • 美容
  • ぜんそく
  • 鬱血性心不全
  • 希少遺伝性疾患
  • マラリア
  • 黒色腫
  • 脳腫瘍
  • 発作

第7章 リソース

付録

図表

目次
Product Code: CP2290

The ‘Trends in Therapeutic Partnering’ report provides the most comprehensive and in-depth insight into the dealmaking trends along therapeutic target lines.

The report provides a detailed understanding and analysis of the most popular therapeutic targets for partnering in the period 2010 to mid 2015. The majority of the deals are discovery, preclinical and clinical stage whereby the licensee obtains a right or an option right to license or accesses the licensors compounds or product candidates. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

One of the key aspects of partnering is finding those companies that are potential candidates for the development and commercialization of the next generation of therapeutic targets. A lot of resources are spent on finding partners, identifying their interests and making contact to initiate discussions.

Using this report, dealmakers will effectively and efficiently target their partnering activities to deliver the company's business development objectives. Over 300 charts allow quick understanding of therapeutic partnering trends since 2010, together with insight into which companies are active in each of the thirty five leading therapeutic areas.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.

The initial chapters of this report provide an orientation of therapeutic dealmaking.

Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of therapeutic dealmaking since 2010, listing the top therapeutic areas for partnering by deal frequency and deal dollars committed by partnering companies.

Chapter 3 reviews the top pharma and biotech therapeutic partnering deals of 2010-2015 according to reported deal size.

Chapter 4 provides a summary on best practice on how to submit an opportunity to the leading therapeutic partnering companies, to ensure building of relationships and to obtain a prompt assessment and response from the business development function of the prospective partner.

Chapter 5 lists forthcoming partnering events where valuable face to face meetings with biopharma companies provide a highly effective means of obtaining interest in novel opportunities. These events are where dealmaking gets initiated through numerous back to back meetings.

The main body of the report is provided in chapter 6. In-depth profiles of each of the top 35 therapeutic target areas according to deal frequency during the period 2010-2015 provide everything required to assess the potential of the therapeutic area and its active partner companies. Each profile includes a partnering activity overview, deal financials (including headline, upfront and royalties rates, where available).

Each therapeutic profile provides a listing of partnering deals for the top fifiteen most active companies in each therapeutic area, and is accompanied by an appendix that provides a comprehensive listing of deal records available at Current Agreements, each of which links direct to an online copy of the actual deal record plus contract document if filed with the SEC.

One of the key aspects of partnering is conducting due diligence on a partner to determine under what terms a prospective partner agrees to a partnering relationship.

Understanding the flexibility of a prospective partners' negiotated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.

This data driven report contains over 5,000 links to online copies of actual deal records at Current Agreements and contract documents, where submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.

In addition, contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.

In summary, the report provides the reader with the tools necessary to understand trends in therapeutic partnering, the most active therapeutic areas in terms of deal frequency and leading deal maker companies, and the deal terms and structures achieved in such therapeutic partnering deals.

Key benefits

‘Trends in Therapeutic Partnering 2010-2015’ report provides the reader with the following key benefits:

  • In-depth understanding of therapeutic partnering trends since 2010
  • Analysis of the top 35 therapeutic target areas for partnering
  • Comprehensive access to over 5,000 actual partnering deals entered into by the world's biopharma companies
  • Detailed access to actual therapeutic partnering deals enter into by the leading fifty bigpharma and bigbiotech companies
  • Insight into the terms included in a therapeutic partnering agreement, together with real world clause examples
  • Understand the key deal terms companies have agreed in previous deals
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Report scope

‘Trends in Therapeutic Partnering’ is intended to provide the reader with an in-depth understanding of therapeutic partnering trends and structure of deals entered into by leading companies worldwide.

‘Trends in Therapeutic Partnering 2010-2015’ report includes:

  • Trends in therapeutic dealmaking in the biopharma industry since 2010
  • Analysis of therapeutic partnering deal structure
  • Access to over 5,000 therapeutic partnering deals
  • The top 35 therapeutic targets for partnering since 2010
  • The leading therapeutic partnering deals by value since 2010
  • Most active therapeutic partnering dealmakers since 2010

In ‘Trends in Therapeutic Partnering 2010-2015’, the available deals are listed by:

  • Most active companies in partnering for each therapeutic area
  • Headline value
  • Upfront payment
  • Royalty rate
  • Company A-Z

Each deal title links to online deal records of actual therapeutic partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The ‘Trends in Therapeutic Partnering 2010-2015’ report provides comprehensive access to available deal records for over 5,000 therapeutic target partnering deals. Analyzing actual contract agreements allows assessment of the following:

  • What are the precise rights granted or optioned?
  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What is the payment structure for the deal?
  • How are sales and payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in therapeutic dealmaking activity

  • 2.1. Introduction
  • 2.2. Leading therapy partnering areas
  • 2.3. Top therapeutic targets for partnering 2010-2015

Chapter 3 - Leading therapy deals by value

  • 3.1. Introduction
  • 3.2. Big pharma therapy partnering
  • 3.3. Big biotech therapy partnering

Chapter 4 - Submitting opportunities to therapeutic target partner companies

  • 4.1. How to submit an opportunity
  • 4.2. Opportunity submission template
  • 4.3. Sending emails
  • 4.4. Face to face at partnering events
  • 4.5. Online submission forms

Chapter 5 - Forthcoming therapeutic partnering events

  • 5.1. Forthcoming events

Chapter 6 - Top 35 therapeutic partnering targets

  • 6.1. Introduction
  • 6.2. Therapeutic profiles

1. Diabetes

  • Diabetes partnering in numbers
  • Top diabetes partnering deals by value
  • Most active diabetes partnering companies

2. Pain CNS

  • Pain partnering in numbers
  • Top pain partnering deals by value
  • Most active pain partnering companies

3. Breast cancer

  • Breast cancer partnering in numbers
  • Top breast cancer partnering deals by value
  • Most active breast cancer partnering companies

4. Alzheimer's disease

  • Alzheimer's disease partnering in numbers
  • Top Alzheimer's disease partnering deals by value
  • Most active Alzheimer's disease partnering companies

5. Wound healing

  • Wound healing partnering in numbers
  • Top wound healing partnering deals by value
  • Most active wound healing partnering companies

6. HIV

  • HIV partnering in numbers
  • Top HIV partnering deals by value
  • Most active HIV partnering companies

7. Inflammation

  • Inflammation partnering in numbers
  • Top Inflammation partnering deals by value
  • Most active inflammation partnering companies

8. Leukemia

  • Leukemia partnering in numbers
  • Top leukemia partnering deals by value
  • Most active leukemia partnering companies

9. Prostate cancer

  • Prostate cancer partnering in numbers
  • Top prostate cancer partnering deals by value
  • Most active prostate cancer partnering companies

10. Solid tumor

  • Solid tumor partnering in numbers
  • Top solid tumors partnering deals by value
  • Most active solid tumor partnering companies

11. Parkinson's disease

  • Parkinson's disease partnering in numbers
  • Top Parkinson's disease partnering deals by value
  • Most active Parkinson's disease partnering companies

12. Lung cancer

  • Lung cancer partnering in numbers
  • Top lung cancer partnering deals by value
  • Most active lung cancer partnering companies

13. Colorectal cancer

  • Colorectal cancer partnering in numbers
  • Top colorectal cancer partnering deals by value
  • Most active colorectal cancer partnering companies

14. Nutrition & Vitamins

  • Nutrition & Vitamins partnering in numbers
  • Top nutrition & vitamins partnering deals by value
  • Most active nutrition & vitamin partnering companies

15. Influenza

  • Influenza partnering in numbers
  • Top influenza partnering deals by value
  • Most active influenza partnering companies
  • PATH (Appropriate Technology in Health)

16. Rheumatoid arthritis

  • Rheumatoid arthritis partnering in numbers
  • Top rheumatoid arthritis partnering deals by value
  • Most active rheumatoid arthritis partnering companies

17. Multiple sclerosis

  • Multiple sclerosis partnering in numbers
  • Top multiple sclerosis partnering deals by value
  • Most active multiple sclerosis partnering companies

18. Lymphoma

  • Lymphoma partnering in numbers
  • Top lymphoma partnering deals by value
  • Most active lymphoma partnering companies

19. Orthopedics

  • Orthopedics partnering in numbers
  • Top Orthopedics partnering deals by value
  • Most active Orthopedics partnering companies

20. Rare Genetics Disorders

  • Rare Genetics Disorders partnering in numbers
  • Top rare genetic disorders partnering deals by value
  • Most active rare genetic disorders partnering companies

21. Ovarian cancer

  • Ovarian cancer partnering in numbers
  • Top ovarian cancer partnering deals by value
  • Most active ovarian cancer partnering companies

22. Transplantation

  • Transplantation partnering in numbers
  • Top transplantation partnering deals by value
  • Most active transplantation partnering companies

23. Orphan Disease

  • Orphan Disease partnering in numbers
  • Top Orphan disease partnering deals by value
  • Most active orphan disease partnering companies

24. Spinal cord

  • Spinal cord partnering in numbers
  • Top spinal cord partnering deals by value
  • Most active spinal cord partnering companies

25. Obesity

  • Obesity partnering in numbers
  • Top obesity partnering deals by value
  • Most active obesity partnering companies

26. Accident & emergency

  • Accident & emergency partnering in numbers
  • Top Accident & emergency partnering deals by value

27. Pancreatic cancer

  • Pancreatic cancer partnering in numbers
  • Top pancreatic cancer partnering deals by value
  • Most active pancreatic cancer partnering companies

28. Tuberculosis

  • Tuberculosis partnering in numbers
  • Top tuberculosis partnering deals by value
  • Most active tuberculosis partnering companies

29. Hepatitis C

  • Hepatitis C partnering in numbers
  • Top hepatitis C partnering deals by value
  • Most active hepatitis C partnering companies

30. Other autoimmune disorders

  • Other autoimmune disorders partnering in numbers
  • Top other autoimmune disorders partnering deals by value
  • Most active other autoimmune disorders partnering companies

31. Melanoma

  • Melanoma partnering in numbers
  • Top melanoma partnering deals by value
  • Most active melanoma partnering companies

32. Congestive heart failure

  • Congestive heart failure partnering in numbers
  • Top congestive heart failure partnering deals by value
  • Most active congestive heart failure partnering companies

33. Cosmetics

  • Cosmetics partnering in numbers
  • Top cosmetics partnering deals by value
  • Most active cosmetics partnering companies

34. Multiple myeloma

  • Multiple myeloma partnering in numbers
  • Top Multiple myeloma partnering deals by value
  • Most active Multiple myeloma partnering companies

35. Asthma

  • Asthma partnering in numbers
  • Top asthma partnering deals by value
  • Most active asthma partnering companies

Chapter 7 - Resources

  • About Wildwood Ventures
  • Current Partnering
  • Current Agreements
  • Recent report titles from Current Partnering

See 3 separate volumes for the following appendices

Appendix volume 1

  • Appendix 1 - Diabetes deal directory - company A-Z
  • Appendix 2 - Pain deal directory - company A-Z
  • Appendix 3 - Breast cancer deal directory - company A-Z
  • Appendix 4 - Alzeimer's disease deal directory - company A-Z
  • Appendix 5 - Wound healing deal directory - company A-Z
  • Appendix 6 -HIV deal directory - company A-Z
  • Appendix 7 - Inflammation deal directory - company A-Z

Appendix volume 2

  • Appendix 8 - Leukemia deal directory - company A-Z
  • Appendix 9 - Prostate cancer deal directory - company A-Z
  • Appendix 10 - Solid tumors deal directory - company A-Z
  • Appendix 11 - Parkinson's disease deal directory - company A-Z
  • Appendix 12 - Lung cancer deal directory - company A-Z
  • Appendix 13 - Colorectal cancer deal directory - company A-Z
  • Appendix 14 - Nutrition & vitamins deal directory - company A-Z
  • Appendix 15 -Influenza deal directory - company A-Z
  • Appendix 16 -Rheumatoid arthritis deal directory - company A-Z
  • Appendix 17 - Multiple sclerosis deal directory - company A-Z

Appendix volume 3

  • Appendix 18 - Lymphoma deal directory - company A-Z
  • Appendix 19 - Orthopedics deal directory - company A-Z
  • Appendix 20 -Rare genetic disorders deal directory - company A-Z
  • Appendix 21 - Ovarian cancer deal directory - company A-Z
  • Appendix 22 - Transplantation deal directory - company A-Z
  • Appendix 23 - Orphan disease deal directory - company A-Z
  • Appendix 24 - Spinal cord deal directory - company A-Z
  • Appendix 25 - Obesity deal directory - company A-Z
  • Appendix 26 - Accident & Emergency deal directory - company A-Z
  • Appendix 27 - Pancreatic cancer deal directory - company A-Z
  • Appendix 28 - Tuberculosis deal directory - company A-Z
  • Appendix 29 - Hepatitis C deal directory - company A-Z
  • Appendix 30 - Other autoimmune disorders deal directory - company A-Z
  • Appendix 31 - Melanoma deal directory - company A-Z
  • Appendix 32 - Congestive heart failure deal directory - company A-Z
  • Appendix 33 - Cosmetics deal directory - company A-Z
  • Appendix 34 - Multiple myeloma deal directory - company A-Z
  • Appendix 35 - Asthma deal directory - company A-Z
  • Appendix 36 - Deal type definitions
  • Appendix 37 - Example contract document

TABLE OF FIGURES

  • Figure 1: Partnering trends by therapy area 2010-2015
  • Figure 2: Top most partnered therapeutics targets 2010-2015
  • Figure 3: Top partnered therapeutic targets by financial value 2010-2015
  • Figure 4: Leading big pharma therapy partnering deals by value, 2010-2015
  • Figure 5: Leading big biotech therapy partnering deals by value, 2010-2015
  • Figure 6: Typical partnering opportunity submission template
  • Figure 7: Diabetes: Partnering frequency 2010-2015
  • Figure 8: Diabetes: most active dealmakers
  • Figure 9: Diabetes: partnering deals by sector
  • Figure 10: Diabetes partnering deals by type
  • Figure 11: Diabetes partnering deals by technology type
  • Figure 12: Diabetes artnering deals by stage of development
  • Figure 13: Diabetes partnering deals by headline value
  • Figure 14: Diabetes: partnering deals by upfront payment
  • Figure 15: Diabetes partnering deals by royalty rate
  • Figure 16: Diabetes: partnering deals 2010-2015 - most active companies
  • Figure 17: Pain: Partnering frequency 2010-2015
  • Figure 18: Pain partnering most active dealmakers
  • Figure 19: Pain partnering deals by sector
  • Figure 20: Pain partnering deals by type
  • Figure 21: Pain partnering deals by technology type
  • Figure 22: Pain partnering deals by stage of development
  • Figure 23: Pain partnering deals by headline value
  • Figure 24: Pain partnering deals by upfront payment
  • Figure 25: Pain partnering deals by royalty rate
  • Figure 26: Pain partnering deals 2010-2015 by most active companies
  • Figure 27: Breast cancer: Partnering frequency 2010-2015
  • Figure 28: Breast cancer most active dealmakers
  • Figure 29: Breast cancer partnering deals by sector
  • Figure 30: Breast cancer partnering deals by type
  • Figure 31: Breast cancer partnering deals by technology type
  • Figure 32: Breast cancer partnering deals by stage of development
  • Figure 33: Breast cancer partnering deals by headline value
  • Figure 34: Breast cancer partnering deals by upfront payment
  • Figure 35: Breast cancer partnering deals by royalty rate
  • Figure 36: Breast cancer partnering deals 2010-2015 by most active companies
  • Figure 37: Alzheimer's disease: Partnering frequency 2010-2015
  • Figure 38: Alzheimer's disease most active dealmakers
  • Figure 39: Alzheimer's disease partnering deals by sector
  • Figure 40: Alzheimer's disease partnering deals by type
  • Figure 41: Alzheimer's disease partnering deals by technology type
  • Figure 42: Alzheimer's disease partnering deals by stage of development
  • Figure 43: Alzheimer's disease partnering deals by headline value
  • Figure 44: Alzheimer's disease partnering deals by upfront payment
  • Figure 45: Alzheimer's disease partnering deals by royalty rate
  • Figure 46: Alzheimer's partnering deals 2010-2015 by most active companies
  • Figure 47: Wound healing: Partnering frequency 2010-2015
  • Figure 48: Wound healing most active dealmakers
  • Figure 49: Wound healing partnering deals by sector
  • Figure 50: Wound healing partnering deals by type
  • Figure 51: Wound healing partnering deals by technology type
  • Figure 52: Wound healing partnering deals by stage of development
  • Figure 53: Wound healing partnering deals by headline value
  • Figure 54: Wound healing partnering deals by upfront payment
  • Figure 55: Wound healing partnering deals by royalty rate
  • Figure 56: Wound healing partnering deals 2010-2015 by most active companies
  • Figure 57: HIV: Partnering frequency 2010-2015
  • Figure 58: HIV most active dealmakers
  • Figure 59: HIV partnering deals by sector
  • Figure 60: HIV partnering deals by type
  • Figure 61: HIV partnering deals by technology type
  • Figure 62: HIV partnering deals by stage of development
  • Figure 63: HIV partnering deals by headline value
  • Figure 64: HIV partnering deals by upfront payment
  • Figure 65: HIV partnering deals by royalty rate
  • Figure 66: HIV partnering deals 2010-2015 by most active companies
  • Figure 67: Inflammation: Partnering frequency 2010-2015
  • Figure 68: Inflammation most active dealmakers
  • Figure 69: Inflammation partnering deals by industry sector
  • Figure 70: Inflammation partnering deals by type
  • Figure 71: Inflammation partnering deals by technology type
  • Figure 72: Inflammation partnering deals by stage of development
  • Figure 73: Inflammation partnering deals by headline value
  • Figure 74: Inflammation partnering deals by upfront payment
  • Figure 75: Inflammation partnering deals by royalty rate
  • Figure 76: Inflammation partnering deals 2010-2015 by most active companies
  • Figure 77: Leukemia: Partnering frequency 2010-2015
  • Figure 78: Leukemia most active dealmakers
  • Figure 79: Leukemia partnering deals by industry sector
  • Figure 80: Leukemia partnering deals by type
  • Figure 81: Leukemia partnering deals by technology type
  • Figure 82: Leukemia partnering deals by stage of development
  • Figure 83: Leukemia partnering deals by headline value
  • Figure 84: Leukemia partnering deals by upfront payment
  • Figure 85: Leukemia partnering deals by royalty rate
  • Figure 86: Leukemia partnering deals 2010-2015 by most active companies
  • Figure 87: Prostate cancer: Partnering frequency 2010-2015
  • Figure 88: Prostate cancer most active dealmakers
  • Figure 89: Prostate cancer partnering deals by industry sector
  • Figure 90: Prostate cancer partnering deals by type
  • Figure 91: Prostate cancer partnering deals by technology type
  • Figure 92: Prostate cancer partnering deals by stage of development
  • Figure 93: Prostate cancer partnering deals by headline value
  • Figure 94: Prostate cancer partnering deals by upfront payment
  • Figure 95: Prostate cancer partnering deals by royalty rate
  • Figure 96: Prostate cancer partnering deals 2010-2015 by most active companies
  • Figure 97: Solid tumor: Partnering frequency 2010-2015
  • Figure 98: Solid tumor most active dealmakers
  • Figure 99: Solid tumor partnering deals by industry sector
  • Figure 100: Solid tumor partnering deals by type
  • Figure 101: Soid tumor partnering deals by technology type
  • Figure 102: Solid tumor partnering deals by stage of development
  • Figure 103: Solid tumor partnering deals by headline value
  • Figure 104: Solid tumor partnering deals by upfront payment
  • Figure 105: Solid tumor partnering deals by royalty rate
  • Figure 106: Solid tumor partnering deals 2010-2015 by most active companies
  • Figure 107: Parkinson's disease: Partnering frequency 2010-2015
  • Figure 108: Parkinson's disease most active dealmakers
  • Figure 109: Parkinson's disease partnering deals by industry sector
  • Figure 110: Parkinson's disease partnering deals by type
  • Figure 111: Parkinson's disease partnering deals by technology type
  • Figure 112: Parkinson's disease partnering deals by stage of development
  • Figure 113: Parkinson's disease partnering deals by headline value
  • Figure 114: Parkinson's disease partnering deals by upfront payment
  • Figure 115: Parkinson's disease partnering deals by royalty rate
  • Figure 116: Parkinson's disease partnering deals 2010-2015 by most active companies
  • Figure 117: Lung cancer: Partnering frequency 2010-2015
  • Figure 118: Lung cancer most active dealmakers
  • Figure 119: Lung cancer partnering deals by sector
  • Figure 120: Lung cancer partnering deals by type
  • Figure 121: Lung cancer partnering deals by technology type
  • Figure 122: Lung cancer partnering deals by stage of development
  • Figure 123: Lung cancer partnering deals by headline value
  • Figure 124: Lung cancer partnering deals by upfront payment
  • Figure 125: Lung cancer partnering deals 2010-2015 by most active companies
  • Figure 126: Colorectal cancer: Partnering frequency 2010-2015
  • Figure 127: Colorectal cancer most active dealmakers
  • Figure 128: Colorectal cancer partnering deals by industry sector
  • Figure 129: Colorectal cancer partnering deals by type
  • Figure 130: Colorectal cancer partnering deals by technology type
  • Figure 131: Colorectal cancer partnering deals by stage of development
  • Figure 132: Colorectal cancer partnering deals by headline value
  • Figure 133: Coloretal cancer partnering deals by upfront payment
  • Figure 134: Colorectal cancer partnering deals by royalty rate
  • Figure 135: Colorectal cancer partnering deals 2010-2015 by most active companies
  • Figure 136: Nutrition & Vitamins: Partnering frequency 2010-2015
  • Figure 137: Nutrition & Vitamins most active dealmakers
  • Figure 138: Nutrition & Vitamins partnering deals by sector
  • Figure 139: Nutrition & Vitamins partnering deals by type
  • Figure 140: Nutrition & Vitamins partnering deals by technology type
  • Figure 141: Nutrition & Vitamins partnering deals by stage of development
  • Figure 142: Nutrition & Vitamins partnering deals by headline value
  • Figure 143: Nutrition & Vitamins partnering deals by upfront payment
  • Figure 144: Nutrition & Vitamins partnering deals by royalty rate
  • Figure 145: Nutrition & Vitamins partnering deals 2010-2015 by most active companies
  • Figure 146: Influenza: Partnering frequency 2010-2015
  • Figure 147: Influenza most active dealmakers
  • Figure 148: Influenza partnering deals by industry sector
  • Figure 149: Influenza partnering deals by type
  • Figure 150: Influenza partnering deals by technology type
  • Figure 151: Influenza partnering deals by stage of development
  • Figure 152: Influenza partnering deals by headline value
  • Figure 153: Influenza partnering deals by upfront payment
  • Figure 154: Influenza partnering deals by royalty rate
  • Figure 155: Influenza partnering deals 2010-2015 by most active companies
  • Figure 156: Rheumatoid arthritis: Partnering frequency 2010-2015
  • Figure 157: Rheumatoid arthritis most active dealmakers
  • Figure 158: Rheumatoid arthritis partnering deals by industry sector
  • Figure 159: Rheumatoid arthritis partnering deals by type
  • Figure 160: Rheumatoid arthritis partnering deals by technology type
  • Figure 161: Rheumatoid arthritis partnering deals by stage of development
  • Figure 162: Rheumatoid arthritis partnering deals by headline value
  • Figure 163: Rheumatoid arthritis partnering deals by upfront payment
  • Figure 164: Rheumatoid arthritis partnering deals by royalty rate
  • Figure 165: Rheumatoid arthritis partnering deals 2010-2015 by most active companies
  • Figure 166: Multiple sclerosis: Partnering frequency 2010-2015
  • Figure 167: Multiple sclerosis most active dealmakers
  • Figure 168: Multiple sclerosis partnering deals by industry sector
  • Figure 169: Multiple sclerosis partnering deals by type
  • Figure 170: Multiple sclerosis partnering deals by technology type
  • Figure 171: Multiple sclerosis partnering deals by stage of development
  • Figure 172: Multiple sclerosis partnering deals by headline value
  • Figure 173: Multiple sclerosis partnering deals by upfront payment
  • Figure 174: Multiple sclerosis partnering deals by royalty rate
  • Figure 175: Multiple sclerosis partnering deals 2010-2015 by most active companies
  • Figure 176: Lymphoma: Partnering frequency 2010-2015
  • Figure 177: Lymphoma most active dealmakers
  • Figure 178: Lymphoma partnering deals by industry sector
  • Figure 179: Lymphoma partnering deals by type
  • Figure 180: Lymphoma partnering deals by technology type
  • Figure 181: Lymphoma partnering deals by stage of development
  • Figure 182: Lymphoma partnering deals by headline value
  • Figure 183: Lymphoma partnering deals by upfront payment
  • Figure 184: Lymphoma partnering deals by royalty rate
  • Figure 185: Lymphoma partnering deals 2010-2015 by most active companies
  • Figure 186: Orthopedics: Partnering frequency 2010-2015
  • Figure 187: Orthopedics most active dealmakers
  • Figure 188: Orthopedics partnering deals by industry sector
  • Figure 189: Orthopedics partnering deals by type
  • Figure 190: Orthopedics partnering deals by technology type
  • Figure 191: Orthopedics partnering deals by stage of development
  • Figure 192: Orthopedics partnering deals by headline value
  • Figure 193: Orthopedics partnering deals by upfront payment
  • Figure 194: Orthopedics partnering deals by royalty rate
  • Figure 195: Orthopedics partnering deals 2010-2015 by most active companies
  • Figure 196: Rare genetic disorders: Partnering frequency 2010-2015
  • Figure 197: Rare genetic disorders most active dealmakers
  • Figure 198: Rare genetic disorders partnering deals by industry sector
  • Figure 199: Rare genetic disorders partnering deals by type
  • Figure 200: Rare genetic disorders partnering deals by technology type
  • Figure 201: Rare genetic disorders partnering deals by stage of development
  • Figure 202: Rare genetic disorders partnering deals by headline value
  • Figure 203: Rare genetic disorders partnering deals by upfront payment
  • Figure 204: Rare genetic disorders partnering deals by royalty rate
  • Figure 205: Rare genetic disorders partnering deals 2010-2015 by most active companies
  • Figure 206: Ovarian cancer: Partnering frequency 2010-2015
  • Figure 207: Ovarian cancer most active dealmakers
  • Figure 208: Ovarian cancer partnering deals by industry sector
  • Figure 209: Ovarian cancer partnering deals by type
  • Figure 210: Ovarian cancer partnering deals by technology type
  • Figure 211: Ovarian cancer partnering deals by stage of development
  • Figure 212: Ovarian cancer partnering deals by headline value
  • Figure 213: Ovarian cancer partnering deals by upfront payment
  • Figure 214: Ovarian cancer partnering deals 2010-2015 by most active companies
  • Figure 215: Transplantation: Partnering frequency 2010-2015
  • Figure 216: Transplantation most active dealmakers
  • Figure 217: Transplantation partnering deals by industry sector
  • Figure 218: Transplantation partnering deals by type
  • Figure 219: Transplantation partnering deals by technology type
  • Figure 220: Transplantation partnering deals by stage of development
  • Figure 221: Transplantation partnering deals by headline value
  • Figure 222: Transplantation partnering deals by upfront payment
  • Figure 223: Transplantation partnering deals by royalty rate
  • Figure 224: Transplantation partnering deals 2010-2015 by most active companies
  • Figure 225: Orphan disease: Partnering frequency 2010-2015
  • Figure 226: Orphan disease most active dealmakers
  • Figure 227: Orphan disease partnering deals by industry sector
  • Figure 228: Orphan disease partnering deals by type
  • Figure 229: Orphan disease partnering deals by technology type
  • Figure 230: Orphan disease partnering deals by stage of development
  • Figure 231: Orphan disease partnering deals by headline value
  • Figure 232: Orphan disease partnering deals by upfront payment
  • Figure 233: Orphan disease partnering deals by royalty rate
  • Figure 234: Orphan disease partnering deals 2010-2015 by most active companies
  • Figure 235: Spinal cord: Partnering frequency 2010-2015
  • Figure 236: Spinal cord most active dealmakers
  • Figure 237: Spinal cord partnering deals by industry sector
  • Figure 238: Spinal cord partnering deals by type
  • Figure 239: Spinal cord partnering deals by technology type
  • Figure 240: Spinal cord partnering deals by stage of development
  • Figure 241: Spinal cord partnering deals by headline value
  • Figure 242: Spinal cord partnering deals by upfront payment
  • Figure 243: Spinal cord partnering deals by royalty rate
  • Figure 244: Spinal cord partnering deals 2010-2015 by most active companies
  • Figure 245: Obesity: Partnering frequency 2010-2015
  • Figure 246: Obesity most active dealmakers
  • Figure 247: Obesity partnering deals by industry sector
  • Figure 248: Obesity partnering deals by type
  • Figure 249: Obesity partnering deals by technology type
  • Figure 250: Obesity partnering deals by stage of development
  • Figure 251: Obesity partnering deals by headline value
  • Figure 252: Obesity partnering deals by upfront payment
  • Figure 253: Obesity partnering deals by royalty rate
  • Figure 254: Obesity partnering deals 2010-2015 by most active companies
  • Figure 255: Accident & emergency: Partnering frequency 2010-2015
  • Figure 256: Accident & emergency most active dealmakers
  • Figure 257: Accident & emergency partnering deals by industry sector
  • Figure 258: Accident & emergency partnering deals by type
  • Figure 259: Accident & emergency partnering deals by technology type
  • Figure 260: Accident & emergency partnering deals by stage of development
  • Figure 261: Accident & emergency partnering deals by headline value
  • Figure 262: Accident & emergency partnering deals by upfront payment
  • Figure 263: Accident & emergency partnering deals 2010-2015 by most active companies
  • Figure 264: Pancreatic cancer: Partnering frequency 2010-2015
  • Figure 265: Pancreatic cancer most active dealmakers
  • Figure 266: Pancreatic cancer partnering deals by industry sector
  • Figure 267: Pancreatic cancer partnering deals by type
  • Figure 268: Pancreatic cancer partnering deals by technology type
  • Figure 269: Pancreatic cancer partnering deals by stage of development
  • Figure 270: Pancreatic cancer partnering deals by headline value
  • Figure 271: Pancreatic cancer partnering deals by upfront payment
  • Figure 272: Pancreatic cancer partnering deals 2010-2015 by most active companies
  • Figure 273: Tuberculosis: Partnering frequency 2010-2015
  • Figure 274: Tuberculosis most active dealmakers
  • Figure 275: Tuberculosis partnering deals by industry sector
  • Figure 276: Tuberculosis partnering deals by type
  • Figure 277: Tuberculosis partnering deals by technology type
  • Figure 278: Tuberculosis partnering deals by stage of development
  • Figure 279: Tuberculosis partnering deals by headline value
  • Figure 280: Tuberculosis partnering deals by upfront payment
  • Figure 281: Tuberculosis partnering deals 2010-2015 by most active companies
  • Figure 282: Hepatitis C: Partnering frequency 2010-2015
  • Figure 283: Hepatitis C most active dealmakers
  • Figure 284: Hepatitis C partnering deals by industry sector
  • Figure 285: Hepatitis C partnering deals by type
  • Figure 286: Hepatitis C partnering deals by technology type
  • Figure 287: Hepatitis C partnering deals by stage of development
  • Figure 288: Hepatitis C partnering deals by headline value
  • Figure 289: Hepatitis C partnering deals by upfront payment
  • Figure 290: Hepatitis C partnering deals 2010-2015 by most active companies
  • Figure 291: Other autoimmune disorders: Partnering frequency 2010-2015
  • Figure 292: Other autoimmune disorders most active dealmakers
  • Figure 293: Other autoimmune disorders partnering deals by industry sector
  • Figure 294: Other autoimmune disorders partnering deals by type
  • Figure 295: Other autoimmune disorders partnering deals by technology type
  • Figure 296: Other autoimmune disorders partnering deals by stage of development
  • Figure 297: Other autoimmune disorders partnering deals by headline value
  • Figure 298: Other autoimmune disorders partnering deals by upfront payment
  • Figure 299: Other autoimmune disorders partnering deals by royalty rate
  • Figure 300: Other autoimmune disorders partnering deals 2010-2015 by most active companies
  • Figure 301: Melanoma: Partnering frequency 2010-2015
  • Figure 302: Melanoma most active dealmakers
  • Figure 303: Melanoma partnering deals by industry sector
  • Figure 304: Melanoma partnering deals by type
  • Figure 305: Melanoma partnering deals by technology type
  • Figure 306: Melanoma partnering deals by stage of development
  • Figure 307: Melanoma partnering deals by headline value
  • Figure 308: Melanoma partnering deals by upfront payment
  • Figure 309: Melanoma partnering deals by royalty rate
  • Figure 310: Melanoma partnering deals 2010-2015 by most active companies
  • Figure 311: Congestive heart failure: Partnering frequency 2010-2015
  • Figure 312: Congestive heart failure most active dealmakers
  • Figure 313: Congestive heart failure partnering deals by industry sector
  • Figure 314: Congestive heart failure partnering deals by type
  • Figure 315: Congestive heart failure partnering deals by technology type
  • Figure 316: Congestive heart failure partnering deals by stage of development
  • Figure 317: Congestive heart failure partnering deals by headline value
  • Figure 318: Congestive heart failure partnering deals by upfront payment
  • Figure 319: Congestive heart failure partnering deals by royalty rate
  • Figure 320: Congestive heart failure partnering deals 2010-2015 by most active companies
  • Figure 321: Cosmetics: Partnering frequency 2010-2015
  • Figure 322: Cosmetics most active dealmakers
  • Figure 323: Cosmetics partnering deals by industry sector
  • Figure 324: Cosmetics partnering deals by type
  • Figure 325: Cosmetics partnering deals by technology type
  • Figure 326: Cosmetics partnering deals by stage of development
  • Figure 327: Cosmetics partnering deals by headline value
  • Figure 328: Cosmetics partnering deals by upfront payment
  • Figure 329: Cosmetics partnering deals by royalty rate
  • Figure 330: Cosmetics partnering deals 2010-2015 by most active companies
  • Figure 331: Multiple myeloma: Partnering frequency 2010-2015
  • Figure 332: Multiple myeloma most active dealmakers
  • Figure 333: Multiple myeloma partnering deals by industry sector
  • Figure 334: Multiple myeloma partnering deals by type
  • Figure 335: Multiple myeloma partnering deals by technology type
  • Figure 336: Multiple myeloma artnering deals by stage of development
  • Figure 337: Multiple myeloma partnering deals by headline value
  • Figure 338: Multiple myeloma partnering deals by upfront payment
  • Figure 339: Multiple myeloma partnering deals by royalty rate
  • Figure 340: Multiple myeloma partnering deals 2010-2015 by most active companies
  • Figure 341: Asthma: Partnering frequency 2010-2015
  • Figure 342: Asthma most active dealmakers
  • Figure 343: Asthma partnering deals by industry sector
  • Figure 344: Asthma partnering deals by type
  • Figure 345: Asthma partnering deals by technology type
  • Figure 346: Asthma partnering deals by stage of development
  • Figure 347: Asthma partnering deals by headline value
  • Figure 348: Asthma partnering deals by upfront payment
  • Figure 349: Asthma partnering deals by royalty rate
  • Figure 350: Asthma partnering deals 2010-2015 by most active companies
  • Figure 351: Online partnering resources
Back to Top